hypertensive patients with left ventricular hypertrophy and asymptomatic hyperuricemia
Conditions
Interventions
experimental group: benzbromarone
Sponsors
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) For patients with primary hypertension aged over 18 years old (referred to 2018 China guidelines for hypertension); (2) Diagnostic criteria for left ventricular hypertrophy (UCG: LVMI, male >115 g/m2; female >95 g/m2); (3) Suspected left ventricular diastolic dysfunction (8420umol/L and 360umol/L and <600umol/L for female in recent 3 months). If urate-lowering medicine were used, serum uric acid value was re-examined 10 days after medicine withdrawal; (6) Volunteer and sign informed consent.
Exclusion criteria
Exclusion criteria: (1) Heart failure (including systolic heart failure and diastolic heart failure); (2) Organic heart disease (coronary heart disease, cardiomyopathy, rheumatic heart disease, congenital heart disease, pulmonary heart disease, etc.); (3) Refractory hypertension; (4) Gout arthritis and kidney stones; (5) Severe renal dysfunction, eGFR 3 ULN, total bilirubin > 2 ULN); (7) Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular diastolic function (E/e'); | — |
Secondary
| Measure | Time frame |
|---|---|
| composite endpoint;LVMI;LVEF;serum uric acid; | — |
Countries
China
Contacts
Public ContactJun Gu
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed